Multibagger pharma penny stock at Rs 12 per share : Plans Rs 80 Crore QIP to Fund Agro-Pharma Research Laboratory; Board is likely to announce 1:1 bonus share & 1:10 stock split
DSIJ Intelligence-2Categories: Mindshare, Penny Stocks, Trending
The stock is up by 97 per cent from its 52-week low of Rs 6.40 per share and has given multibagger returns of 630 per cent in 5 years.
WELCURE DRUGS & PHARMACEUTICALS LTD has announced its plan to establish an Agro-Pharma Research Laboratory and raise up to Rs 80 crore through a Qualified Institutional Placement (QIP). The company has scheduled a Board of Directors meeting on August 28, 2025, to consider and potentially approve the fund-raising proposal.
The proposed Agro-Pharma Research Laboratory aims to focus on research, validation, and scaling of processes to convert agricultural and botanical inputs into pharma-grade products. These products are intended to address public health needs and enhance societal well-being. The company also intends to align its facilities and processes with cGMP standards and the US FDA’s Botanical Drug Development guidance, which could enable participation in international markets for botanical and ayurvedic products, subject to necessary approvals.
DSIJ’s 'Tiny Treasure' service recommends researched Small-Cap stocks with Inherent Growth Potential. If this interests you, download the service details here.
The estimated project cost is between Rs 70–80 crore, covering laboratory infrastructure, pilot lines, analytics, and quality systems. Implementation details, including site, timeline, and commissioning, will be disclosed after approvals in line with SEBI Listing Obligations and Disclosure Requirements (LODR).
The industry context highlights a strong opportunity for compliant and evidence-based agro-derived therapeutics. Independent estimates suggest the global herbal and botanical medicine market was valued at USD 70.6 billion in 2023 and is projected to reach USD 328.7 billion by 2030, at a CAGR of around 21 per cent. Botanical supplements were valued at USD 38.2 billion in 2024, projected to grow at a CAGR of 9.9 per cent by 2030. In India, the ayurvedic products market stood at Rs 876 billion in 2024, with an expected CAGR of 16 per cent until 2033.
The proposed QIP aims to raise up to Rs 80 crore, in one or more tranches, to primarily finance the Agro-Pharma Research Laboratory and for general corporate purposes.
Advertisement:
50% OFF on DSIJ Digital Magazine
The Board meeting on August 28, 2025, will consider and, if appropriate, approve the enabling resolutions, issue structure, and seek shareholders’ approval for the QIP. The company clarified that the proposal does not involve any related-party transactions. In compliance with insider trading norms, the trading window will remain closed until 48 hours after the outcome of the meeting is disclosed.
WELCURE DRUGS & PHARMACEUTICALS LTD, represented by Director Chintan Didawala Ganpat, reaffirmed its commitment to timely and transparent disclosures. The company also noted that certain statements are forward-looking and subject to risks and uncertainties. Actual outcomes may differ based on approvals and market conditions.
The stock is up by 97 per cent from its 52-week low of Rs 6.40 per share and has given multibagger returns of 630 per cent in 5 years.
Disclaimer: The article is for informational purposes only and not investment advice.